Link between COVID-19 and IMU?

https://*********.com.au/imugenes-pd1-vaxx-treatment-trialled-patients-lung-cancer/

Imugene also wants to develop a selection of B-cell therapies that can stimulate the patient’s immune system to produce polyclonal antibodies, and very importantly, introduce a slew of benefits including lower costs, better efficacy and lower cancer recurrence rates.

https://sciencespeaksblog.org/2020/02/12/immune-survivors-of-covid-19-protective-antibody-for-treatment-and-prophylaxis/

In the absence of licensed antiviral drugs or vaccines for COVID-19, how might plasma and B-cell donation from such survivors help?

Immune plasma with polyclonal antibodies against the virus could be studied in a clinical trial to determine if it helps treat infected patients at risk for, or who already have, serious disease.

Could either immune plasma polyclonal antibody, or a monoclonal antibody developed from specific B-cells, be studied in clinical trials not only for treatment of patients, but also for prophylaxis (prevention) of disease?

Yes, for both pre-exposure prophylaxis (PrEP) and also for post-exposure prophylaxis (PEP).

"Given reports of health care personnel being infected and insufficient personal protective equipment (PPE) in some parts of China, how might such antibody approaches help?

Potentially as a treatment and also as prophylaxis (PrEP and PEP) against COVID-19. (The half-life of some polyclonal antibodies against other pathogens is approximately 3 weeks)